277 related articles for article (PubMed ID: 26669913)
1. Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study.
Coates LC; Helliwell PS
J Rheumatol; 2016 Feb; 43(2):356-61. PubMed ID: 26669913
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate achieves major cDAPSA response, and improvement in dactylitis and functional status in psoriatic arthritis.
Appani SK; Devarasetti PK; Irlapati RVP; Rajasekhar L
Rheumatology (Oxford); 2019 May; 58(5):869-873. PubMed ID: 30590763
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH
Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
[TBL] [Abstract][Full Text] [Related]
4. Results of one-year treat-to-target strategy in early psoriatic arthritis: data of an open-label REMARCA study.
Korotaeva TV; Loginova EY; Getiya TS; Nasonov EL
Ter Arkh; 2018 May; 90(5):22-29. PubMed ID: 30701886
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.
Walsh JA; Gottlieb AB; Hoepken B; Nurminen T; Mease PJ
Clin Rheumatol; 2018 Dec; 37(12):3285-3296. PubMed ID: 30191421
[TBL] [Abstract][Full Text] [Related]
6. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
7. GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis.
Vieira-Sousa E; Alves P; Rodrigues AM; Teixeira F; Tavares-Costa J; Bernardo A; Pimenta S; Pimentel-Santos FM; Gomes JL; Aguiar R; Pinto P; Videira T; Catita C; Santos H; Borges J; Sequeira G; Ribeiro C; Teixeira L; Ávila-Ribeiro P; Martins FM; Canhão H; McInnes IB; Ribeiro RM; Fonseca JE
Ann Rheum Dis; 2020 Apr; 79(4):490-498. PubMed ID: 32193187
[TBL] [Abstract][Full Text] [Related]
8. Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study.
Baranauskaite A; Raffayová H; Kungurov NV; Kubanova A; Venalis A; Helmle L; Srinivasan S; Nasonov E; Vastesaeger N;
Ann Rheum Dis; 2012 Apr; 71(4):541-8. PubMed ID: 21994233
[TBL] [Abstract][Full Text] [Related]
9. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.
Zintzaras E; Dahabreh IJ; Giannouli S; Voulgarelis M; Moutsopoulos HM
Clin Ther; 2008 Nov; 30(11):1939-55. PubMed ID: 19108784
[TBL] [Abstract][Full Text] [Related]
10. Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study.
Mease PJ; Gladman DD; Deodhar A; McGonagle DG; Nash P; Boehncke WH; Gottlieb A; Xu XL; Xu S; Hsia EC; Karyekar CS; Helliwell PS
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32665433
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Etanercept Monotherapy and Combination Therapy with Methotrexate in Psoriatic Arthritis: Results from 2 Clinical Trials.
Combe B; Behrens F; McHugh N; Brock F; Kerkmann U; Kola B; Gallo G
J Rheumatol; 2016 Jun; 43(6):1063-7. PubMed ID: 27134249
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials.
Kivitz AJ; FitzGerald O; Nash P; Pang S; Azevedo VF; Wang C; Takiya L
Clin Rheumatol; 2022 Feb; 41(2):499-511. PubMed ID: 34510295
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial.
Ritchlin C; Rahman P; Kavanaugh A; McInnes IB; Puig L; Li S; Wang Y; Shen YK; Doyle MK; Mendelsohn AM; Gottlieb AB;
Ann Rheum Dis; 2014 Jun; 73(6):990-9. PubMed ID: 24482301
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2.
McInnes IB; Chakravarty SD; Apaolaza I; Kafka S; Hsia EC; You Y; Kavanaugh A
RMD Open; 2019; 5(2):e000990. PubMed ID: 31565242
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis.
McInnes IB; Rahman P; Gottlieb AB; Hsia EC; Kollmeier AP; Xu XL; Jiang Y; Sheng S; Shawi M; Chakravarty SD; van der Heijde D; Mease PJ
Arthritis Rheumatol; 2022 Mar; 74(3):475-485. PubMed ID: 34719872
[TBL] [Abstract][Full Text] [Related]
16. Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA).
Mulder MLM; Vriezekolk JE; den Broeder N; Mahler EAM; Helliwell PS; van den Hoogen FHJ; den Broeder AA; Wenink MH
Trials; 2020 Feb; 21(1):155. PubMed ID: 32041657
[TBL] [Abstract][Full Text] [Related]
17. Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial.
Helliwell PS; Mease PJ; Kavanaugh A; Coates LC; Ogdie A; Deodhar A; Strand V; Kricorian G; Liu LXH; Collier D; Gladman DD
RMD Open; 2022 Jul; 8(2):. PubMed ID: 35863864
[TBL] [Abstract][Full Text] [Related]
18. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.
Coates LC; Moverley AR; McParland L; Brown S; Navarro-Coy N; O'Dwyer JL; Meads DM; Emery P; Conaghan PG; Helliwell PS
Lancet; 2015 Dec; 386(10012):2489-98. PubMed ID: 26433318
[TBL] [Abstract][Full Text] [Related]
19. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study.
Gladman DD; ; Sampalis JS; Illouz O; Guérette B
J Rheumatol; 2010 Sep; 37(9):1898-906. PubMed ID: 20595284
[TBL] [Abstract][Full Text] [Related]
20. Phase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate.
Mease PJ; Genovese MC; Weinblatt ME; Peloso PM; Chen K; Othman AA; Li Y; Mansikka HT; Khatri A; Wishart N; Liu J
Arthritis Rheumatol; 2018 Nov; 70(11):1778-1789. PubMed ID: 29855175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
